SLC5A2 and type 2 diabetes mellitus: Gliflozins including empagliflozin, dapagliflozin, and canagliflozin are a novel class of antidiabetic agents used for the treatment of T2DM that selectively inhibit SGLT2 to prevent glucose reabsorption in the renal proximal tubule.